Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$43.00
-2.00 (-4.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.1B · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-77.1%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-2.15B · FCF $-2.12B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $40.5M |
| Net Income | $-2.15B | $-2.15B | $-1.32B | $-2.39B | $-2.70B |
| EBITDA | $-2.15B | $-2.15B | $-1.31B | $-2.39B | $-2.58B |
| EPS | — | — | -28.57 | -77.24 | -92.85 |
| Operating Margin | — | — | — | — | -5094.3% |
| Net Margin | — | — | — | — | -6673.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.30 | — |
| Current Ratio | 25.13 | 25.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.12B | $-2.12B | $-1.43B | $-2.29B | $-2.09B |
| Returns | |||||
| ROE | -77.1% | -77.1% | -37.1% | -173.3% | -91.9% |
| Valuation | |||||
| P/B | 1.19 | 1.19 | 1.33 | 2.58 | 3.20 |
| Growth & Yield | |||||
| EPS Growth | — | — | 63.0% | 16.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-28.57 → n/d
Residual
-46.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.